glucopyranosyl trichloroacetimidate | 141839-43-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: glucopyranosyl trichloroacetimidate
• 英文别名: [(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 2,2,2-trichloroethanimidate
• CAS: 141839-43-2
• 化学式: C₈H₁₂Cl₃NO₆
• 分子量: 324.545
• InChiKey: CGWVAQMLSHXXQE-GASJEMHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  123
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-O-[3″,4″-di-O-methyl-β-d-xylopyranosyl]diphyllin 、 glucopyranosyl trichloroacetimidate 在 三氟化硼乙醚 作用下， 以 二氯甲烷 为溶剂， 反应 3.17h， 以64%的产率得到cleistanthoside A tetraacetate
  参考文献：
  名称：

  Synthesis and identification of cytotoxic diphyllin glycosides as vacuolar H+-ATPase inhibitors

  摘要：

  The concise syntheses of two natural diphyllin glycosides Cleistanthin-A (CA), Cleistanthoside-A (CleA) and its derivative, Cleistanthoside-A tetraacetate (CleT), have been achieved. They were evaluated for their in vitro anti-proliferative activities against MCF-7, HeLa, HepG2, HCT-116, U251 cancer cell lines by MTT assay. Both of CA and CleT were anti-proliferative to these cancer cells at nanomolar concentrations. They have been shown to inhibit the activity of vacuolar H+-ATPase (V-ATPase) in HepG2 cells and neutralize the pH of lysosomes at nanomolar concentrations. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.06.002

文献信息

• FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：DRIGUEZ Pierre Alexandre

  公开号：US20120214754A1

  公开（公告）日：2012-08-23

  The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R 1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R 2 is an OSO 3 − or hydroxyl group, R 3 is an alkyl, cycloalkyl, or alkyl-cycloalkyl group, R 4 is a disaccharide having Formula (II), R 6 is a disaccharide having Formula (III), and R 8 is a disaccharide having Formula (IV), where R 5 , R 7 , and R 9 are OSO 3 − or hydroxyl groups. The invention further relates to the preparation of said octasaccharides and to the therapeutic use thereof.

  该发明涉及具有化学式（I）的FGF受体激活N-酰基八糖，其中：R1是一个可选地由一个或多个芳基或环烷基取代的O-烷基基团，R2是一个OSO3−或羟基，R3是一个烷基、环烷基或烷基-环烷基基团，R4是具有化学式（II）的二糖，R6是具有化学式（III）的二糖，R8是具有化学式（IV）的二糖，其中R5、R7和R9是OSO3−或羟基基团。该发明还涉及所述八糖的制备以及其治疗用途。
• TRITERPENES DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS OR ANTI-INFLAMMATORY AGENTS
  申请人：PICHETTE ANDRE

  公开号：US20080167254A1

  公开（公告）日：2008-07-10

  A compound of formula (1): wherein R 1 is selected from the group consisting of H, α-L-Rhamnopyranose, α-D-Mannopyranose, β-D-Xylopyranose, β-D-Glucopyranose, and α-D-Arabinopyranose; R 2 is selected from CH 3 , COOH, CH 2 OH, COOCH 3 and CH 2 O-α-D-Arabinopyranose; with the proviso that the compound of formula (I) is not a compound of formula (I) wherein R 1 is β-D-Glucopyranose and R 2 is COOH; wherein R 1 is α-L-Rhamnopyranose and R 2 is CH 3 ; wherein R 1 is β-D-Glucopyranose and R 2 is CH 2 OH; wherein R 1 is β-D-Xylopyranose and R 2 is CH 2 OH; wherein R 1 is α-L-Rhamnopyranose and R 2 is COOCH 3 , wherein R 1 is H and R 2 is CH 3 ; wherein R 1 is H and R 2 is CH 2 OH; wherein R 1 is H and R 2 is COOH; or wherein R 1 is H and R 2 is COOCH 3 , or a pharmaceutically acceptable salt thereof.

  式（1）的化合物：其中R1选自H、α-L-葡萄糖苷、α-D-甘露糖苷、β-D-木糖苷、β-D-葡萄糖苷和α-D-阿拉伯糖苷组成的群；R2选自CH3、COOH、 H、COO 和CH2O-α-D-阿拉伯糖苷；但化合物的式（I）不是式（I）中R1为β-D-葡萄糖苷且R2为COOH的化合物；其中R1为α-L-葡萄糖苷且R2为 ；其中R1为β-D-葡萄糖苷且R2为 H；其中R1为β-D-木糖苷且R2为 H；其中R1为α-L-葡萄糖苷且R2为COO ；其中R1为H且R2为 ；其中R1为H且R2为 H；其中R1为H且R2为COOH；或其中R1为H且R2为COO ，或其药学上可接受的盐。
• HEPARAN SULFATE/HEPARIN MIMETICS WITH ANTI-CHEMOKINE AND ANTI-INFLAMMATORY ACTIVITY
  申请人：California Institute of Technology

  公开号：US20150038455A1

  公开（公告）日：2015-02-05

  The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods.

  本公开提供了一系列合成糖聚合物的方法和组合物。该公开还涉及一种适用于执行创新方法的试剂盒。
• TAILORED GLYCOPOLYMERS AS ANTICOAGULANT HEPARIN MIMETICS
  申请人：California Institute of Technology

  公开号：US20150038436A1

  公开（公告）日：2015-02-05

  The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods.

  本公开提供了一系列合成糖聚合物的方法和组合物。该公开还涉及一种适用于实施创新方法的试剂盒。
• [EN] SYNTHETIC POLYSACCHARIDES, THEIR METHOD OF PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME<br/>[FR] POLYSACCHARIDES DE SYNTHESE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LE CONTENANT
  申请人：SANOFI-SYNTHELABO

  公开号：WO1999036443A1

  公开（公告）日：1999-07-22

  (EN) The invention relates to synthetic polysaccharides in an acid form and their pharmaceutically acceptable salts, the anionic form of which complies with one of the formulas (I) to (V) described in claim 1. Said polysaccharides can be used in the treatment of diseases linked to coagulation disorders.(FR) La présente invention concerne des polysaccharides de synthèse sous forme acide et leurs sels pharmaceutiquement acceptables, dont la forme anionique répond à l'une des formules (I) à (V) définies à la revendication 1. Ces polysaccharides sont utilisables dans le traitement de pathologies dépendantes d'un dysfonctionnement de la coagulation.

  (中) 本发明涉及酸性合成多糖及其药学上可接受的盐，其阴离子形式符合权利要求1中描述的公式(I)至(V)之一。这些多糖可用于治疗与凝血障碍相关的疾病。